Grand Piano,Grand Pianos Musical Instruments,Classical Grand Piano,Concert Grand Piano Yantai Kingsburg Piano Co.,Ltd , https://www.kingsburgpianosales.com
There are 1,025 chemical raw material companies in the country, including 22 large-scale enterprises, 149 medium-sized enterprises and 854 small-scale enterprises. Statistics show that from January to August this year, the national chemical raw materials medicine industry realized a total industrial output value of 98.483 billion yuan, an increase of 26.01%; completed sales value of 94.161 billion yuan, an increase of 25.14%. Among them, the industrial output value of small enterprises accounted for 36.01% of the entire industry, large enterprises accounted for only 29.09%. The sales value of small businesses completed 34.127 billion yuan, accounting for 36.24% of the entire industry, an increase of 32.54%, higher than the industry average of 7.4 percentage points; while large-scale enterprises only completed 27.543 billion yuan, accounting for only 29.25% of the entire industry, an increase of the same period 20.48%, below the industry average of 4.66 percentage points.
From January to August, China's chemical raw material medicine industry realized a total profit of 6.299 billion yuan, an increase of 36.10% year-on-year, small enterprises accounted for 34.51% of total profits, and large enterprises accounted for only 24.29%. From January to August, China's chemical raw material medicine industry was 7.12% in the cost of small businesses, 5.68% in large companies, and 1.44 points in large enterprises.
From the perspective of the size of the company’s assets, small companies in the chemical raw material pharmaceutical industry increased more, with assets increasing by 19.34% year-on-year, and large-scale enterprises increasing by 1.46% year-on-year. However, from the proportion of total assets, large-scale enterprise assets accounted for 37.07%, small-scale enterprises only It accounts for 26.26%.
Among the assets of the chemical raw material medicine industry, the state-owned economy accounted for 23.36%, down by 0.91% year-on-year; the joint-stock economy accounted for 45.36%, an increase of 8.76% year-on-year. From the perspective of the type of holding, private companies account for 41.6% of the total assets of the industry, and state-controlled enterprises account for 37.27% of the total assets of the industry. This is the two major types of companies in the chemical bulk pharmaceutical industry, and privately-held companies continue to expand and grow year-on-year. 15.22%, foreign-funded enterprises and China's Hong Kong, Macao, and Taiwan controlled-type enterprises are continuously expanding their scale, and their growth rate is far higher than the average level. The continuous expansion of other economic types of enterprises has brought severe challenges to state-controlled chemical raw material drug companies, especially large state-owned enterprises with long history.
The return on total assets of the chemical raw material medicine industry was 5.04%. Among them, the return rate of assets of state-controlled enterprises is the lowest, only 3.51%. The relatively high rate of return is the controlling enterprises and foreign-controlled enterprises in China's Hong Kong, Macao and Taiwan regions, which were 7.46% and 6.39%, respectively. The return rate of assets of large-scale enterprises was not good enough, only 3.68%, and that of small-scale enterprises was 6.06%.
All kinds of data show that if large-scale chemical raw material enterprises in China want to enter the scientific development track, they must learn from the development experience of small enterprises, accelerate the pace of reform and reform, vigorously promote technological innovation, and strengthen internal management so as to continuously improve profitability.
Big companies seem to be stronger than small businesses. However, the chemical raw material medicine industry has broken this law. According to the latest statistical data, although large enterprises in China's chemical raw material pharmaceutical industry have an advantage in terms of total assets, their industrial output value, sales output value, total profit, cost-cost profit ratio and return on assets are not as good as economic indicators. Businesses do not show advantages.